Anticipated Sale of Antibiotics on U.S. Market Boosts Price of Lek Shares
Ljubljana, 8 April - Shares of the Slovene pharmaceutical company Lek saw a staggering growth in March, gaining almost 20 percent in a single month of trading on the Ljubljana Stock Exchange. According to Austrian bank Reiffeisen Zentralbank (RZB), the growth is attributable to speculations about the upcoming sale of Lek's antibiotic Amoksiklav on the U.S. market, the largest market for pharmaceuticals in the world, the business daily Finance writes on Monday.
The rest of this news item is available to subscribers.
The news item consists of 1.192 characters (without spaces) or 236 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.